Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
复制标题
DOI：
10.1186/s12967-022-03592-4
复制
发表时间：
2022-09-04
影响因子：
7.4
通讯作者：
Thurin, Magdalena
中科院分区：
文献类型：
--
作者：
Ascierto, Paolo A.;Agarwala, Sanjiv S.;Blank, Christian;Caraco, Corrado;Carvajal, Richard D.;Ernstoff, Marc S.;Ferrone, Soldano;Fox, Bernard A.;Gajewski, Thomas F.;Garbe, Claus;Grob, Jean-Jacques;Hamid, Omid;Krogsgaard, Michelle;Lo, Roger S.;Lund, Amanda W.;Madonna, Gabriele;Michielin, Olivier;Neyns, Bart;Osman, Iman;Peters, Solange;Poulikakos, Poulikos, I;Quezada, Sergio A.;Reinfeld, Bradley;Zitvogel, Laurence;Puzanov, Igor;Thurin, Magdalena
关键词：
免疫检查点和联合治疗的进展改善了晚期黑色素瘤患者的总生存期。对肿瘤、肿瘤微环境和肿瘤免疫逃避机制的进一步理解导致了靶向和利用宿主免疫应答的新方法。与其他免疫治疗剂、化学疗法、放射疗法、电化学疗法的组合方式也正在探索中，以克服耐药性并增强免疫应答。此外，新的方法，如过继细胞治疗，致癌病毒，疫苗和不同的药物管理策略，包括顺序或组合治疗正在测试中。尽管黑素细胞病变的诊断取得了进展，但患者的正确分类、适当辅助和全身治疗的选择以及对治疗反应的预测仍然是黑色素瘤的真实的挑战。对肿瘤微环境、肿瘤免疫和对治疗的反应的更好理解促进了对黑色素瘤的广泛转化和临床研究。越来越多的证据表明，治疗前肿瘤活检的基因组和免疫特征可能与黑色素瘤和其他癌症患者的反应相关，但它们尚未完全表征和临床实施。新型生物标志物平台的开发可能有助于提高诊断和预测准确性，以选择患者进行特定治疗。总体而言，未来黑色素瘤治疗和转化研究的研究工作应集中在几个方面，包括：（a）开发稳健的生物标志物以预测治疗方式的功效，从而指导临床决策并优化治疗方案，（B）鉴定对免疫检查点抑制剂的治疗抗性的机制，所述机制是潜在可行的，（c）鉴定生物标志物以预测治疗诱导的不良事件，和（d）研究治疗剂的作用机制并开发算法以优化组合治疗。在Melanoma Bridge会议期间（2021年12月2日至4日，意大利那不勒斯），讨论重点是目前批准的晚期黑色素瘤全身和局部治疗，并讨论了新型生物标志物策略和精准医学的进展以及COVID-19大流行对黑色素瘤患者管理的影响。
Advances in immune checkpoint and combination therapy have led to improvement in overall survival for patients with advanced melanoma. Improved understanding of the tumor, tumor microenvironment and tumor immune-evasion mechanisms has resulted in new approaches to targeting and harnessing the host immune response. Combination modalities with other immunotherapy agents, chemotherapy, radiotherapy, electrochemotherapy are also being explored to overcome resistance and to potentiate the immune response. In addition, novel approaches such as adoptive cell therapy, oncogenic viruses, vaccines and different strategies of drug administration including sequential, or combination treatment are being tested. Despite the progress in diagnosis of melanocytic lesions, correct classification of patients, selection of appropriate adjuvant and systemic theràapies, and prediction of response to therapy remain real challenges in melanoma. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers, but they have yet to be fully characterized and implemented clinically. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. Overall, the future research efforts in melanoma therapeutics and translational research should focus on several aspects including: (a) developing robust biomarkers to predict efficacy of therapeutic modalities to guide clinical decision-making and optimize treatment regimens, (b) identifying mechanisms of therapeutic resistance to immune checkpoint inhibitors that are potentially actionable, (c) identifying biomarkers to predict therapy-induced adverse events, and (d) studying mechanism of actions of therapeutic agents and developing algorithms to optimize combination treatments. During the Melanoma Bridge meeting (December 2nd-4th, 2021, Naples, Italy) discussions focused on the currently approved systemic and local therapies for advanced melanoma and discussed novel biomarker strategies and advances in precision medicine as well as the impact of COVID-19 pandemic on management of melanoma patients.
登录
查看更多内容
影响因子：
28.2
作者：
Adamopoulos C;Ahmed TA;Tucker MR;Ung PMU;Xiao M;Karoulia Z;Amabile A;Wu X;Aaronson SA;Ang C;Rebecca VW;Brown BD;Schlessinger A;Herlyn M;Wang Q;Shaw DE;Poulikakos PI
通讯作者：
Poulikakos PI
影响因子：
64.5
作者：
Cui C;Wang J;Fagerberg E;Chen PM;Connolly KA;Damo M;Cheung JF;Mao T;Askari AS;Chen S;Fitzgerald B;Foster GG;Eisenbarth SC;Zhao H;Craft J;Joshi NS
通讯作者：
Joshi NS
影响因子：
32.4
作者：
Ehx, Gregory;Larouche, Jean-David;Perreault, Claude
通讯作者：
Perreault, Claude
影响因子：
8.4
作者：
Clover, A. J. P.;de Terlizzi, F.;Gehl, J.
通讯作者：
Gehl, J.
影响因子：
16.6
作者：
Dubin K;Callahan MK;Ren B;Khanin R;Viale A;Ling L;No D;Gobourne A;Littmann E;Huttenhower C;Pamer EG;Wolchok JD
通讯作者：
Wolchok JD